Zobrazeno 1 - 10 of 129 pro vyhledávání: '"Etienne Giroux Leprieur"'
1
Akademický článek
Validation of Liquid Chromatography Coupled with Tandem Mass Spectrometry for the Determination of 12 Tyrosine Kinase Inhibitors (TKIs) and Their Application to Therapeutic Drug Monitoring in Adult and Pediatric Populations
Autor: Marie Bellouard, Jean Donadieu, Pauline Thiebot, Etienne Giroux Leprieur, Philippe Saiag, Isabelle Etting, Pamela Dugues, Emuri Abe, Jean-Claude Alvarez, Islam-Amine Larabi
Publikováno v: Pharmaceutics, Vol 16, Iss 1, p 5 (2023)
Tyrosine kinase inhibitors (TKIs) are used as targeted cancer therapies in adults and have an off-label pediatric application for the treatment of Langerhans cell histiocytosis. A multitarget LC-MS/MS method was developed and validated for the determ
Externí odkaz: https://doaj.org/article/4652bf71bb0b4d0eaf12ccc05c0b7f90
Zobrazit plný text záznamu
2
Akademický článek
Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study
Autor: Geoffroy Bilger, Anne-Claire Toffart, Marie Darrason, Michaël Duruisseaux, Lucie Ulmer, Pascal Wang, Etienne Giroux Leprieur, Nicolas Girard, Marie Ange Massiani, Paul Bore, Renaud Descourt, Julian Pinsolle, Solene Valery, Isabelle Monnet, Aurélie Swalduz, Claire Tissot, Pierre Fournel, Anne Baranzelli, Alexis B. Cortot, Chantal Decroisette
Publikováno v: Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Introduction: Compared with docetaxel, the phase-III trial, ULTIMATE, showed a significant improvement of progression-free survival (PFS) with paclitaxel–bevacizumab combination (PB) as second- or third-line treatment in advanced non-small cell lu
Externí odkaz: https://doaj.org/article/dacbea286c6e4222a88af607dd501e41
Zobrazit plný text záznamu
3
Akademický článek
Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab
Autor: Julia Ouaknine Krief, Pierre Helly de Tauriers, Coraline Dumenil, Nathalie Neveux, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Julie Tisserand, Catherine Julie, Jean-François Emile, Thierry Chinet, Etienne Giroux Leprieur
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Recent data suggested a role of gut microbiota and antibiotic use on immune checkpoint inhibitors efficacy. We aimed to evaluate the impact of early use of antibiotic (EUA), blood microbiome and plasmatic citrulline (marker of the
Externí odkaz: https://doaj.org/article/1ac16da7d72d4360a71cc08abea4aa14
Zobrazit plný text záznamu
5
Akademický článek
Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression
Autor: Jean-François Emile, Coraline Dumenil, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Catherine Julie, Thierry Chinet, Etienne Giroux Leprieur, Zofia Hélias-Rodzewicz, Paul Takam Kamga, Adrien Costantini, Alexandre Corjon, Simon Garinet
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Despite prolonged tumor response to immune checkpoint inhibitors (ICIs) for a subset of patients with advanced non-small cell lung cancer (NSCLC), a secondary resistance will occur for a majority of these patients. The understanding of lat
Externí odkaz: https://doaj.org/article/03dd415e5a6e46c3a728013a99b7763e
Zobrazit plný text záznamu
6
Akademický článek
Successful pulmonary arterial embolization followed by curative surgery for a lepidic predominant lung adenocarcinoma with severe hypoxemia
Autor: Louise Sebane, Mostafa El-Hajjam, Philippe Puyo, Elisabeth Longchampt, Etienne Giroux Leprieur
Publikováno v: BMC Surgery, Vol 18, Iss 1, Pp 1-3 (2018)
Abstract Background Lepidic predominant adenocarcinoma is characterized by frequent refractory hypoxemia due to intrapulmonary shunting. Severe hypoxemia can induce perioperative complications in case of thoracic surgery. Case presentation We report
Externí odkaz: https://doaj.org/article/432355162d554e1cb4cda2b3f129fff1
Zobrazit plný text záznamu
7
Akademický článek
Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients.
Autor: Philippine Dacosta-Noble, Adrien Costantini, Coraline Dumenil, Jennifer Dumoulin, Pierre Helly de Tauriers, Violaine Giraud, Sylvie Labrune, Jean-François Emile, Jean-Claude Alvarez, Thierry Chinet, Etienne Giroux Leprieur
Publikováno v: PLoS ONE, Vol 14, Iss 7, p e0219080 (2019)
INTRODUCTION:Patients with advanced non-small cell lung cancer (NSCLC) are most of the time treated with a first-line cytotoxic chemotherapy. Tobacco use is responsible for 90% of lung cancer. The aim of this study was to evaluate the impact of smoki
Externí odkaz: https://doaj.org/article/cb29f49b0a6c420eb743f97664e3bf32
Zobrazit plný text záznamu
8
Akademický článek
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
Autor: Adrien Costantini, Catherine Julie, Coraline Dumenil, Zofia Hélias-Rodzewicz, Julie Tisserand, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Jean-François Emile, Etienne Giroux Leprieur
Publikováno v: OncoImmunology, Vol 7, Iss 8 (2018)
Immune checkpoint inhibitors, as nivolumab, are used in advanced non-small cell lung cancer (NSCLC). However, no associated biomarker is validated in clinical practice with this drug. We investigated herein immune-related blood markers in patients wi
Externí odkaz: https://doaj.org/article/da287e26617f4bc5a35c7d66a6731c6a
Zobrazit plný text záznamu
9
Akademický článek
Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
Autor: Etienne Giroux Leprieur, Guillaume Herbretau, Coraline Dumenil, Catherine Julie, Violaine Giraud, Sylvie Labrune, Jennifer Dumoulin, Julie Tisserand, Jean-François Emile, Hélène Blons, Thierry Chinet
Publikováno v: OncoImmunology, Vol 7, Iss 5 (2018)
Nivolumab is an anti-PD1 antibody, given in second-line or later treatment in advanced non-small cell lung cancer (NSCLC). The objective of this study was to describe the predictive value of circulating tumor DNA (ctDNA) on the efficacy of nivolumab
Externí odkaz: https://doaj.org/article/b85a14a64db44194ab6d9474fb505465
Zobrazit plný text záznamu
10
Akademický článek
Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab.
Autor: Coraline Dumenil, Marie-Ange Massiani, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Etienne Giroux Leprieur
Publikováno v: PLoS ONE, Vol 13, Iss 4, p e0195945 (2018)
The prognosis of advanced non-small-cell lung cancer (NSCLC) has been improved by development of immune checkpoint inhibitors (ICIs) such as nivolumab for second-line treatment. As phase III trials include only selected patients, we here investigated
Externí odkaz: https://doaj.org/article/8314a72e39144f31b5b5794b2d9b3cee
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje